Modified CEA nucleic acid and expression vectors
View Patent ↗The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
1. An isolated expression vector for expressing carcinoembryonic antigen (CEA) in a cell, the vector comprising the nucleic acid molecule of SEQ ID NO.: 28.
2. The expression vector of claim 1 wherein the vector is a plasmid or a viral vector.
3. The expression vector of claim 2 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
4. The expression vector of claim 3 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowipox, and TROVAC.
5. The expression vector of claim 4 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6. The expression vector of claim 1 further comprising at least one additional nucleic acid encoding a tumor-associated antigen.
7. The expression vector of claim 6 wherein the vector is a plasmid or a viral vector.
8. The expression vector of claim 7 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
9. The expression vector of claim 8 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10. The expression vector of claim 9 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
11. The expression vector of claim 1 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
12. The expression vector of claim 11 wherein the vector is a plasmid or a viral vector.
13. The expression vector of claim 12 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
14. The expression vector of claim 13 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
15. The expression vector of claim 14 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
16. The expression vector of claim 6 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
17. The expression vector of claim 16 wherein the vector is a plasmid or a viral vector.
18. The expression vector of claim 17 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
19. The expression vector of claim 18 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
20. The expression vector of claim 19 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
21. The expression vector of claim 1 , 6 , 11 or 16 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
22. The expression vector of claim 21 wherein the vector is a plasmid or a viral vector.
23. The expression vector of claim 22 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
24. The expression vector of claim 23 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
25. The expression vector of claim 24 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
26. A composition comprising an isolated expression vector comprising the nucleic acid sequence of SEQ ID NO.: 28 and a pharmaceutically acceptable carrier.
27. The composition of claim 26 wherein the vector is a plasmid or a viral vector.
28. The composition of claim 27 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
29. The composition of claim 28 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
30. The composition of claim 29 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
31. An isolated DNA molecule comprising the nucleic acid sequence of SEQ ID NO.: 28.
32. An isolated expression vector comprising the nucleic acid of SEQ ID NO: 28.
33. The expression vector of claim 32 further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
34. The expression vector of claim 33 wherein the co-stimulatory molecule is human B7.1.
35. The expression vector of claim 32 further comprising a nucleic acid sequence encoding at least one additional tumor-associated antigen.
36. The expression vector of claim 32 further comprising a nucleic acid sequence encoding at least one angiogenesis-associated antigen.
37. A composition comprising an expression vector of any one of claims 32 - 36 in a pharmaceutically acceptable carrier.
38. An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 28.
39. An isolated nucleic acid molecule comprising a CEA-encoding nucleic acid sequence including at least the sequence set forth by 421-1490 of SEQ ID NO.: 28.
40. The isolated nucleic acid molecule of claim 38 or 39 further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
41. The isolated nucleic acid molecule of claim 40 wherein the co-stimulatory molecule is human B7.1.
42. The isolated nucleic acid molecule of claim 38 or 39 further comprising a nucleic acid sequence encoding at least one additional tumor-associated antigen.
43. The isolated nucleic acid molecule of claim 38 or 39 further comprising a nucleic acid sequence encoding at least one angiogenesis-associated antigen.
44. A composition comprising a nucleic acid molecule of any one of claims 38 - 43 in a pharmaceutically acceptable carrier.